AbCellera

Cofounder, Chief Technology Officer and board member of AbCellera who co-invented the company's high-throughput microfluidic antibody discovery platform. She previously served as COO from 2019 to 2025 and holds a PhD in Chemical and Biological Engineering from UBC.

Leads AbCellera's Discovery team with nearly 15 years in biologics development. He was previously Senior Director of Biologics Lead Antibody Discovery at Teva Pharmaceuticals.

CFO of AbCellera since 2019 who helped take the company public on Nasdaq in 2020. He previously served as CFO and Chief Commercial Officer at STEMCELL Technologies and holds an MBA from INSEAD.

VP of Operations at AbCellera overseeing procurement, enterprise data systems, and operational processes. He was previously COO at STEMCELL Technologies.

VP of Business Development at AbCellera who serves on the boards of LifeSciences BC and Aequus Pharmaceuticals. She previously co-founded Northview Lifesciences and was COO of Aequus Pharmaceuticals.

VP of Quality at AbCellera with nearly 30 years of biopharmaceutical experience. He was previously Chief Quality Officer at Biocon Biologics and spent 15 years at Genentech/Roche.

VP of Alliance Management at AbCellera with over 20 years in biopharma. He previously was Senior Director at Halozyme and cofounded Sirenas.

Leads Talent Development at AbCellera, including talent discovery, people support, learning and development, and internal communications. She previously was Managing Director of Student Development and Services at UBC.

Principal of Tower Beach Capital and former Vice Chair of RBC Wealth Management and CEO of RBC Global Asset Management. He serves on several boards including the Canada Pension Plan Investment Board and Aritzia.

President and CEO of Lyell Immunopharma and former CEO of Myovant Sciences. She previously led clinical development of Xtandi as CMO of Medivation.

A Killam Professor of Medical Genetics at UBC and Canada Research Chair who has founded multiple biotech companies and previously served as CSO and President of Global R&D at Teva.

Leads AbCellera's research, partnership, and license agreements with experience in technology commercialization. He previously worked at Harvard's Office of Technology Development and Lux Research.

A senior leader of the Complex Membrane Protein Technologies team who heads an AbCellera location, with over 20 years in protein expression platforms. He joined via AbCellera's 2020 acquisition of TetraGenetics.

CMO of AbCellera responsible for advancing the company's pipeline, a board-certified physician-scientist with over 20 years of experience. She previously held CMO roles at Metagenomi and Maze Therapeutics.

VP of Research Partnerships at AbCellera, managing discovery programs with over 20 years of biotech management experience and expertise in immunology and single-cell assays.

Professor of Bioengineering and Applied Physics at Stanford and former founding co-president of the Chan Zuckerberg Biohub. He has cofounded more than a dozen companies in microfluidics, genomics, and therapeutics.

Leads AbCellera's communications including corporate, media, investor, and scientific communications. She previously cofounded Centrifuge Media Lab and held roles in the STEMCELL Group of Companies.

VP of Facilities at AbCellera leading campus development and facilities operations with over 30 years of health, safety, and facilities experience. She previously directed facilities at QLT and founded MTY Consulting Group.

A legal and compliance executive with over 20 years in biotech and pharma. Before AbCellera he was a partner at Gibbons P.C. and is a former U.S. Naval Officer.

A pharmaceutical and biotech executive with over 20 years of experience, previously Chief Medical Officer at Array BioPharma. He serves on the boards of ADC Therapeutics, Kymera, and Prelude Therapeutics.